The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer.

Ann Oncol

Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9A, Boston, MA 02114. Electronic address:

Published: December 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2023.10.792DOI Listing

Publication Analysis

Top Keywords

elaine trials
4
trials future
4
future personalized
4
personalized therapy
4
therapy hormone-receptor
4
hormone-receptor positive
4
positive metastatic
4
metastatic breast
4
breast cancer
4
elaine
1

Similar Publications

We study the effect of the Scottish three-verdict system (guilty, not guilty, not proven) and the Anglo-American two-verdict system (guilty, not guilty) on juror decisions by combining data sets from 10 mock trials reported in suitable studies. A logistic regression with random effects uses the exact number of convictions and acquittals in 10 mock trials from a total of 1778 jurors to reliably estimate the effect of verdict system. We found a statistically significant verdict effect suggesting that the odds for a conviction by a juror are about 0.

View Article and Find Full Text PDF

Background: Lasofoxifene, a novel endocrine therapy (ET), showed antitumor activity versus fulvestrant in women with ESR1-mutated, metastatic breast cancer (mBC) that progressed on prior ET (phase 2, ELAINE 1 study). We investigated changes in genitourinary syndrome of menopause (GSM) vulvar-vaginal symptoms with lasofoxifene and how patient/disease characteristics affect baseline vulvar-vaginal symptoms in ELAINE 1.

Methods: Women were randomized to oral lasofoxifene 5 mg/day or IM fulvestrant 500 mg (days 1, 15, and 29, then every 28 days) until disease progression/severe toxicity.

View Article and Find Full Text PDF

In-vitro fertilization (IVF) has been a transformative advancement in assisted reproductive technology. However, success rates remain suboptimal, with only about one-third of cycles resulting in pregnancy and fewer leading to live births. This narrative review explores the potential of artificial intelligence (AI), machine learning (ML), and deep learning (DL) to enhance various stages of the IVF process.

View Article and Find Full Text PDF

Systematic review on the effectiveness of Brucella abortus S19 and RB51 vaccine strains in field studies.

Vaccine

January 2025

Departamento de Medicina Veterinária, Faculdade de Zootecnia e Medicina Veterinária, Universidade Federal de Lavras - UFLA, Lavras, Minas Gerais, Brazil. Electronic address:

Brucella abortus S19 and RB51 are the most used vaccines to control bovine brucellosis worldwide; therefore, this study aimed to perform a systematic review on the effectiveness of these two vaccine strains in field studies. The literature review was conducted on April 3rd 2020 on six databases (CABI, Cochrane, PubMed, Scielo, Scopus and Web of Science) and included papers published between 1976 and 2016. The search strategy recovered a total of 5846 papers on databases and 6 papers were included due to specialists' suggestions.

View Article and Find Full Text PDF

Background: S-pindolol has metabolic effects of potential benefit in cancer cachexia: reduced catabolism through nonselective β-blockade; increased anabolism through partial β2 receptor agonism; and increased appetite and reduced fatigue through central 5-hydroxytryptamine/serotonin receptor activity. A Phase 2a clinical trial demonstrated that S-pindolol can reverse weight loss and improve fat-free mass in patients with cancer-related weight loss. A comparative phase I bioavailability study of S-pindolol and racemic pindolol was performed to support the development of S-pindolol in cancer cachexia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!